DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2rk5sl/commercial) has announced the addition of the "Commercial Potential of the Forthcoming US Biosimilars Market" report to their offering.
The report assesses physicians' willingness to prescribe biosimilars in the United States. The objective of this research was to conduct a highly qualitative analysis of a representative sample of 20 preselected practicing specialty physicians in the United States in the spirit of an interactive roundtable discussion.
The primary goal was to encourage participants to freely express opinions and ideas around all aspects of a topic, facilitating a free exchange about how biosimilars will impact their practice and the overall US healthcare market. The biosimilar research panel was conducted over a three-day period (October 11-13, 2011). Questions and discussions were designed to gauge both short-term and long-term trends and impacts.
This research was not intended to produce quantitative data.
The panel consisted of 20 specialty physicians: seven oncologists, seven rheumatologists, and 6 hematologists. Panel participants were randomly selected from a pool of prescreened, qualified candidates and mainly represented hospitals and independent practices across the United States. Selection of specialty practices was based on the therapy area of those biosimilar agents anticipated to enter the US market in the foreseeable future.
- The arrival of biosimilars, or highly similar copies of biopharmaceutical products, to the US market is imminent. Although the products have been available elsewhere -including Europe- for several years, physicians and other key stakeholders in the United States have only recently begun to anticipate their arrival.
- This panel discussion was conducted to preview the thoughts and expectations of specialty physicians who would be expected to be among the first customers of biosimilars, with the objective of gaining insight into some of the major factors that could influence market uptake.
- Based on this representative sample of physicians, the overall adoption of biosimilars can be expected to experience a widespread uptake due to anticipated access to comparable therapeutic options at a lower cost versus high-cost biologics. Main factors with the potential to influence the rate and extent of uptake include cost, safety and efficacy data including testing in specific patient populations, and reputation of the manufacturer.
- Potential skepticism may be overcome with the help of convincing noninferiority clinical data for products from reputable companies that are highly experienced with biologics. Educational programs deemed to be unbiased that convey this data could help increase awareness and boost physician confidence in biosimilar products.
Key Topics Covered
- Executive Summary
- Background Briefing
- Physician Prescribing Behavior
- Customer Purchasing Behavior
- Regulatory Environment
- Biosimilar Manufacturers
For more information visit http://www.researchandmarkets.com/research/2rk5sl/commercial
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.